ACADIA Pharmaceuticals (ACAD) : $0.51 million worth of transactions were on upticks in ACADIA Pharmaceuticals (ACAD), compared to $0.17 million on downticks. The ratio between the two was 3.07, whereas, the net money flow stood at a healthy $0.34 million on Thursdays session. The consistent buying on upticks in the stock accounted for $0.4million worth of trades. The total money flow into the stock stood at $0.4 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -1.22%. The stock was trading at $32.52, with a drop of $0.4 over the previous days close. The stock recorded -6.07% for the week.
The stock has recorded a 20-day Moving Average of 4.3% and the 50-Day Moving Average is 3.9%. Shares have dropped -30.33% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $51.99 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $35.67 and the 200 Day Moving Average price is recorded at $28.29.
ACADIA Pharmaceuticals (NASDAQ:ACAD): The stock opened at $33.31 on Thursday but the bulls could not build on the opening and the stock topped out at $33.38 for the day. The stock traded down to $32.01 during the day, due to lack of any buying support eventually closed down at $32.62 with a loss of -0.91% for the day. The stock had closed at $32.92 on the previous day. The total traded volume was 1,241,222 shares.
In an insider trading activity,The (EVP AND GC) of Acadia Pharmaceuticals Inc, Baity Glenn sold 7,000 shares at $20.8 on March 2, 2016. The Insider selling transaction had a total value worth of $145,600. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.